Lethal neuroleptic malignant syndrome due to amisulpride

Forensic Science, Medicine, and Pathology

Volumn 9, Issue 2, 2013, Pages 218-220

  Musshoff, Frank ^a   Doberentz, Elke ^a   Madea, Burkhard ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

Amisulpride; Fatality; Neuroleptic malignant syndrome (NMS)

Indexed keywords

EID: 84876440095     PISSN: 1547769X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12024-013-9410-1     Document Type: Article

References (21)

1. Trollor JN, Chen X, Sachdev PS. Neuroleptic malignant syndrome associated with atypical antipsychotic drugs. CNS Drugs. 2009; 23: 477-92.
2. Guzofski S, Peralta R. Neuroleptic malignant syndrome, with attention to its occurrence with atypical antipsychotic medication: a review. Jeff J Psych. 2006; 20(1): 54-61.
3. Addonizio G, Susman VL, Roth SD. Symptoms of neuroleptic malignant syndrome in 82 consecutive inpatients. Am J Psychiatry. 1986; 143: 1587-90.
4. American Psychiatric Association. Diagnostic and statistical manual. 4th ed. (text revision). Arlington, VA: American Psychiatric Publishing; 2000.
5. Levenson JL. Neuroleptic malignant syndrome. Am J Psychiatry. 1985; 142: 1137-45.
6. Musshoff F, Kröner L, Padosch SA, Madea B. Fatal intoxication with amisulpride and presentation of organ distribution. Arch Kriminol. 2005; 215: 158-63.
7. Schulz M, Iwersen-Bergmann S, Andresen H, Schmoldt A. Therapeutic and toxic blood concentrations of nearly 1000 drugs and other xenobiotics. Crit Care. 2012; 16(4): R136.
8. Tracqui A, Mutter-Schmidt C, Kintz P, Berton C, Mangin P. Amisulpride poisoning: a report on two cases. Hum Exp Toxicol. 1995; 14: 294-8.
9. Isbister GK, Murray L, John S, Hackett LP, Haider T, O'Mullane P, Gosselin S, Daly F. Amisulpride deliberate self-poisoning causing severe cardiac toxicity including QT prolongation and torsades de pointes. Med J Aust. 2006; 184: 354-6.
10. Lynch MJ, Woods J, George N, Gerostamoulos D. Fatality due to amisulpride toxicity: a case report. Med Sci Law. 2008; 48: 173-7.
11. Curran MP, Perry CM. Amisulpride: a review of its use in the management of schizophrenia. Drugs. 2001; 61: 2123-50.
12. Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002; 17: 1-13.
13. Dorne R, Pommier C, Manchon M, Berny C. Intoxication with amisulpride (Solian): a case with toxicologic documentations. Therapie. 2000; 55: 325-8.
14. Bottlender R, Jager M, Hofschuster E, Dobmeier P, Moller HJ. Neuroleptic malignant syndrome due to atypical neuroleptics: three episodes in one patient. Pharmacopsychiatry. 2002; 35: 119-21.
15. Atbasoglu EC, Ozguven HD, Can Saka M, Goker C. Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome. J Clin Psychiatry. 2004; 65(12): 1724-5.
16. Abay E, Kose R. Amisulpride-induced neuroleptic malignant syndrome. J Neuropsychiatry Clin Neurosci. 2007; 19: 488-9.
17. Harter C, Obier C, Druschky KF, Eikelmann B. Malignant neuroleptic syndrome associated with amisulpride. Nervenarzt. 2008; 79: 86-9.
18. Peritogiannis V, Tsouli S, Pappas D, Mavreas V, Konitsiotis S. Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy. Clin Neuropharmacol. 2007; 30: 245-6.
19. Tu MC, Hsiao CC. Amisulpride and neuroleptic malignant syndrome. Chang Gung Med J. 2011; 34: 536-40.
20. Pope HG Jr, Keck PE Jr, McElroy SL. Frequency and presentation of neuroleptic malignant syndrome in a large psychiatric hospital. Am J Psychiatry. 1986; 143: 1227-33.
21. Adityanjee PA. The spectrum concept and prevalence of neuroleptic malignant syndrome. Am J Psychiatry. 1988; 145(8): 1041.